Posted by Adam Awdish on
Pooled Human AB Serum Off The Clot from Innovative Research was used in the following study:
Ryusuke Hayashi, Toshihiro Nagato, Takumi Kumai, Kenzo Ohara, Mizuho Ohara, Takayuki Ohkuri, Yui Hirata-Nozaki, Shohei Harabuchi, Akemi Kosaka, Marino Nagata, Yuki Yajima, Syunsuke Yasuda, Kensuke Oikawa, Michihisa Kono, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Esteban Celis, Yasuaki Harabuchi, and Hiroya Kobayashi
December 29, 2020
Various cancers of the head and neck are frequent around the globe, with the most common type being head and neck squamous cell carcinoma (HNSCC). Although recent improvements in treatment have reduced the mortality rate associated with HNSCC, more than 65% of patients later develop recurrent metastatic diseases. Peptide vaccines were investigated as a possible treatment and preventative measure for these later diseases; however, they were shown to have weak efficacy in preclinical trials.
Placenta-specific 1 (PLAC1) is commonly expressed in placental trophoblasts, however it doesn’t appear in normal tissues, making it a potential biomarker and treatment target for cancer immunotherapy. This study looked into the presence of PLAC1 in tumors and the way it interacts with the body, specifically T-cells that target specific tumors and antigens. The findings suggest that PLAC1 could be a target antigen for helper T lymphocyte (HTL) immunotherapy.
Related products available from Innovative Research also include: